Literature DB >> 33633565

Protective Effects of Pterostilbene on Lipopolysaccharide-Induced Acute Lung Injury in Mice by Inhibiting NF-κB and Activating Nrf2/HO-1 Signaling Pathways.

Yong Zhang1, Zhen Han1, Aimin Jiang1, Di Wu1, Shuangqiu Li1, Ziyi Liu1, Zhengkai Wei2, Zhengtao Yang2, Changming Guo1.   

Abstract

Pterostilbene (PTER) is a kind of stilbene compound with biological activity isolated from plants such as red sandalwood, blueberry and grape. It has anti-tumor, anti-bacterial, anti-oxidation and other pharmacological activities. However, the underlying mechanism of the protective effect of PTER on lipopolysaccharide (LPS)-induced acute lung injury (ALI) remained not clarified. In this study, LPS was used to establish a mouse model of ALI. Bronchoalveolar lavage fluid (BALF) was collected for inflammatory cells, and the wet-to-dry weight ratio of the lungs was measured. The activities of myeloperoxidase (MPO), antioxidant indexes such as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px) and oxidation index such as malondialdehyde (MDA) in lung tissues of mice were measured by the corresponding kits. The levels of Cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), TNF-α, IL-6 and IL-1β in lung tissues of mice were detected by quantitative real-time polymerase chain reaction (qRT-PCR). The activities of Nrf2, HO-1, p-p65 and p-IκB were determined by western blotting. The results showed that the model of LPS-induced ALI was successfully replicated, and it was found that PTER could significantly improve the pathological degree of ALI such as sustained the integrity of the lung tissue structure, alleviated pulmonary interstitial edema and alveolar wall thickening, reduced infiltrated inflammatory cells. PTER could decrease the number of inflammatory cells and obviously inhibit the increase of W/D ratio caused by LPS. PTER could also significantly reduce LPS-induced MPO and MDA, and increase LPS-decreased SOD, CAT and GSH-Px in the lungs. In addition, it was also found that PTER has the ability to decrease LPS-induced production of COX-2, iNOS, TNF-α, IL-6 and IL-1β. The underlying mechanism involved in the protective effect of PTER on ALI were via activating Nrf2 and HO-1, and inhibiting the phosphorylation of p65 and IκB. These results suggested that PTER can protect LPS-induced ALI in mice by inhibiting inflammatory response and oxidative stress, which provided evidence that PTER may be a potential therapeutic candidate for LPS-induced ALI intervention.
Copyright © 2021 Zhang, Han, Jiang, Wu, Li, Liu, Wei, Yang and Guo.

Entities:  

Keywords:  acute lung injury; inflammatory response; lipopolysaccharide; oxidative stress; pterostilbene

Year:  2021        PMID: 33633565      PMCID: PMC7901969          DOI: 10.3389/fphar.2020.591836

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  49 in total

1.  Molecular targets of the natural antioxidant pterostilbene: effect on protein kinase C, caspase-3 and apoptosis in human neutrophils in vitro.

Authors:  Tomas Perecko; Katarina Drabikova; Lucia Rackova; Milan Ciz; Martina Podborska; Antonin Lojek; Juraj Harmatha; Jan Smidrkal; Radomir Nosal; Viera Jancinova
Journal:  Neuro Endocrinol Lett       Date:  2010       Impact factor: 0.765

Review 2.  Clinical trials in acute respiratory distress syndrome: challenges and opportunities.

Authors:  Michael A Matthay; Daniel F McAuley; Lorraine B Ware
Journal:  Lancet Respir Med       Date:  2017-05-26       Impact factor: 30.700

3.  Protective effect of florfenicol on acute lung injury induced by lipopolysaccharide in mice.

Authors:  Xuemei Zhang; Keji Song; Huanzhang Xiong; Hongyu Li; Xiao Chu; Xuming Deng
Journal:  Int Immunopharmacol       Date:  2009-09-17       Impact factor: 4.932

4.  Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity.

Authors:  Connie M Remsberg; Jaime A Yáñez; Yusuke Ohgami; Karina R Vega-Villa; Agnes M Rimando; Neal M Davies
Journal:  Phytother Res       Date:  2008-02       Impact factor: 5.878

5.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

6.  Microparticles in red cell concentrates prime polymorphonuclear neutrophils and cause acute lung injury in a two-event mouse model.

Authors:  Rufeng Xie; Yiming Yang; Yueyue Zhu; Li Gao; Xueyu Jiang; Juan Sun; Maohong Bian; Jie Yang
Journal:  Int Immunopharmacol       Date:  2017-12-22       Impact factor: 4.932

7.  Partial role of multiple pathways in infarct size limiting effect of quercetin and rutin against cerebral ischemia-reperfusion injury in rats.

Authors:  A Annapurna; M A Ansari; P M Manjunath
Journal:  Eur Rev Med Pharmacol Sci       Date:  2013-02       Impact factor: 3.507

8.  New thiazolidinedione LPSF/GQ-2 inhibits NFκB and MAPK activation in LPS-induced acute lung inflammation.

Authors:  Laise Aline Martins Dos Santos; Gabriel Barros Rodrigues; Fernanda Virgínia Barreto Mota; Maria Eduarda Rocha de França; Karla Patrícia de Souza Barbosa; Wilma Helena de Oliveira; Sura Wanessa Santos Rocha; Deniele Bezerra Lós; Amanda Karolina Soares Silva; Teresinha Gonçalves da Silva; Christina Alves Peixoto
Journal:  Int Immunopharmacol       Date:  2018-02-22       Impact factor: 4.932

9.  Melatonin protects against arsenic trioxide-induced liver injury by the upregulation of Nrf2 expression through the activation of PI3K/AKT pathway.

Authors:  Yue Zhang; Zhengkai Wei; Weijian Liu; Jingjing Wang; Xuexiu He; Hailong Huang; Jiali Zhang; Zhengtao Yang
Journal:  Oncotarget       Date:  2017-01-17

10.  Pterostilbene 4'-β-Glucoside Attenuates LPS-Induced Acute Lung Injury via Induction of Heme Oxygenase-1.

Authors:  Jeongmin Park; Yingqing Chen; Min Zheng; Jinhyun Ryu; Gyeong Jae Cho; Young-Joon Surh; Daisuke Sato; Hiroki Hamada; Stefan W Ryter; Uh-Hyun Kim; Yeonsoo Joe; Hun Taeg Chung
Journal:  Oxid Med Cell Longev       Date:  2018-10-23       Impact factor: 6.543

View more
  6 in total

1.  Dimethyl fumarate ameliorates lipopolysaccharide-induced acute lung injury by inhibiting NLRP3 inflammasome-mediated pyroptosis through enhancing Nrf2 signaling.

Authors:  Huayu Li; Mengyan Li; Chao Dong; Bing Liu
Journal:  Toxicol Res (Camb)       Date:  2022-05-14       Impact factor: 2.680

2.  The Acid Sphingomyelinase Inhibitor Amitriptyline Ameliorates TNF-α-Induced Endothelial Dysfunction.

Authors:  Yang Ji; Jing Chen; Lihua Pang; Changnong Chen; Jinhao Ye; Hao Liu; Huanzhen Chen; Songhui Zhang; Shaojun Liu; Benrong Liu; Chuanfang Cheng; Shiming Liu; Yun Zhong
Journal:  Cardiovasc Drugs Ther       Date:  2022-09-14       Impact factor: 3.947

3.  Deuterated Arachidonic Acid Ameliorates Lipopolysaccharide-Induced Lung Damage in Mice.

Authors:  Alla Y Molchanova; Svetlana N Rjabceva; Tigran B Melik-Kasumov; Nikolay B Pestov; Plamena R Angelova; Vadim V Shmanai; Olga L Sharko; Andrei V Bekish; Genevieve James; Hui Gyu Park; Irina A Udalova; J Thomas Brenna; Mikhail S Shchepinov
Journal:  Antioxidants (Basel)       Date:  2022-03-31

4.  Ramelteon protects against human pulmonary microvascular endothelial cell injury induced by lipopolysaccharide (LPS) via activating nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway.

Authors:  Wenjun Yang; Yang Zhang; Dahao Lu; Tianfeng Huang; Keshi Yan; Weiwei Wang; Ju Gao
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

Review 5.  Thioredoxin-interacting protein (TXNIP) as a target for Alzheimer's disease: flavonoids and phenols.

Authors:  Meng Zhang; Guanhua Hu; Nan Shao; Yunpeng Qin; Qian Chen; Yan Wang; Peng Zhou; Biao Cai
Journal:  Inflammopharmacology       Date:  2021-08-04       Impact factor: 4.473

6.  Pterostilbene pre-treatment reduces LPS-induced acute lung injury through activating NR4A1.

Authors:  Ying Li; Shu-Min Wang; Xing Li; Chang-Jun Lv; Ling-Yun Peng; Xiao-Feng Yu; Ying-Jian Song; Cong-Jie Wang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.